Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study
Combining TKIs with PD-1 inhibitors is an effective and well-tolerated option for HCC patients with Child-Pugh B, including those with CP8/9.
Authors
- Lei Sun (ORCID: https://orcid.org/0000-0002-5640-937X)
- Linlin Zheng (ORCID: https://orcid.org/0000-0002-8902-1056)
- Xiaoyan Ding (ORCID: https://orcid.org/0000-0001-5787-4401)
- Ying Teng (ORCID: https://orcid.org/0000-0002-1527-2856)
- Lin Zhou (ORCID: https://orcid.org/0000-0002-6428-7392)
- Yanjun Shen
- Mei Liu (ORCID: https://orcid.org/0000-0002-4960-0096)
- Wendong Li (ORCID: https://orcid.org/0000-0001-8344-419X)
- Jinglong Chen (ORCID: https://orcid.org/0000-0002-5767-823X)
- Wei Sun (ORCID: https://orcid.org/0000-0001-7511-529X)
- Yawen Xu (ORCID: https://orcid.org/0009-0008-4674-2348)
- Xue Yin (ORCID: https://orcid.org/0009-0002-6805-4593)
- Junke Hu
Institutions
- Capital Medical University (CN)
- Chinese PLA General Hospital (CN)
- Guangdong Province Environmental Monitoring Center (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-05-05
- DOI
- https://doi.org/10.2340/1651-226x.2025.42652
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00